Knight Therapeutics Inc. (GUD.TO)
| Previous close | 5.87 |
| Open | 5.82 |
| Bid | 5.73 x 0 |
| Ask | 5.75 x 0 |
| Day's range | 5.73 - 5.85 |
| 52-week range | 4.35 - 6.22 |
| Volume | |
| Avg. volume | 71,538 |
| Market cap | 595.078M |
| Beta (5Y monthly) | 0.46 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.16 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.19 |
Simply Wall St.Knight Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Knight Therapeutics ( TSE:GUD ) First Quarter 2024 Results Key Financial Results Revenue: CA$86.6m (up 4.9% from 1Q...
GlobeNewswireKnight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive supply and distribution agreement with Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Ironshore Therapeutics, Inc. (“Ironshore”), granting Knight the rights to seek regulatory approval and commercialize JORNAY PM® in Canada and Latin America. Currently approved in the
- GlobeNewswire
Knight Therapeutics Reports First Quarter 2024 Results
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2024. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. 2024 Highlights Financial results Revenues were $86,604, an increase of $4,007 or 5% over the same period in prior y
